Proposed Data Collection Submitted for Public Comment and Recommendations, 17600-17602 [2021-06882]

Download as PDF 17600 Federal Register / Vol. 86, No. 63 / Monday, April 5, 2021 / Notices Authority: Government in the Sunshine Act, 5 U.S.C. 552b. FEDERAL RESERVE SYSTEM Change in Bank Control Notices; Acquisitions of Shares of a Bank or Bank Holding Company Laura E. Sinram, Acting Secretary and Clerk of the Commission. [FR Doc. 2021–07093 Filed 4–1–21; 4:15 pm] BILLING CODE 6715–01–P FEDERAL RESERVE SYSTEM Formations of, Acquisitions by, and Mergers of Bank Holding Companies jbell on DSKJLSW7X2PROD with NOTICES The companies listed in this notice have applied to the Board for approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 1841 et seq.) (BHC Act), Regulation Y (12 CFR part 225), and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or bank holding company and all of the banks and nonbanking companies owned by the bank holding company, including the companies listed below. The public portions of the applications listed below, as well as other related filings required by the Board, if any, are available for immediate inspection at the Federal Reserve Bank(s) indicated below and at the offices of the Board of Governors. This information may also be obtained on an expedited basis, upon request, by contacting the appropriate Federal Reserve Bank and from the Board’s Freedom of Information Office at https://www.federalreserve.gov/foia/ request.htm. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)). Comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors, Ann E. Misback, Secretary of the Board, 20th Street and Constitution Avenue NW, Washington, DC 20551–0001, not later than May 5, 2021. A. Federal Reserve Bank of San Francisco (Sebastian R. Astrada, Director, Applications) 101 Market Street, San Francisco, California 94105– 1579: 1. Peak Bancorp, Inc., McCall, Idaho; to become a bank holding company by acquiring Idaho First Bank, McCall, Idaho. Board of Governors of the Federal Reserve System, March 31, 2021. Michele Taylor Fennell, Deputy Associate Secretary of the Board. [FR Doc. 2021–06944 Filed 4–2–21; 8:45 am] BILLING CODE P VerDate Sep<11>2014 17:23 Apr 02, 2021 Jkt 253001 The notificants listed below have applied under the Change in Bank Control Act (Act) (12 U.S.C. 1817(j)) and § 225.41 of the Board’s Regulation Y (12 CFR 225.41) to acquire shares of a bank or bank holding company. The factors that are considered in acting on the applications are set forth in paragraph 7 of the Act (12 U.S.C. 1817(j)(7)). The public portions of the applications listed below, as well as other related filings required by the Board, if any, are available for immediate inspection at the Federal Reserve Bank(s) indicated below and at the offices of the Board of Governors. This information may also be obtained on an expedited basis, upon request, by contacting the appropriate Federal Reserve Bank and from the Board’s Freedom of Information Office at https://www.federalreserve.gov/foia/ request.htm. Interested persons may express their views in writing on the standards enumerated in paragraph 7 of the Act. Comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors, Ann E. Misback, Secretary of the Board, 20th Street and Constitution Avenue NW, Washington DC 20551–0001, not later than April 20, 2021. A. Federal Reserve Bank of Minneapolis (Chris P. Wangen, Assistant Vice President), 90 Hennepin Avenue, Minneapolis, Minnesota 55480–0291: 1. The Bank Share Marital Trust under the R. James Gesell Declaration of Trust dated January 13, 2000, as amended (Bank Share Marital Trust), and Andrew J. Gesell, individually and as co-trustee with Heidi R. Gesell of the Bank Share Marital Trust, all of St. Paul, Minnesota; to acquire additional voting shares of Cherokee Bancshares, Inc., and thereby indirectly acquire additional voting shares of BankCherokee, both of St. Paul, Minnesota. Additionally, Bank Share Marital Trust; Charles R. Gesell, individually and as trustee of the Charles R. Gesell Trust Declaration under agreement dated December 30, 1999, both of Santa Rosa, California; and Peter J. Gesell, individually and as trustee of the Peter J. Gesell Trust Declaration under agreement dated December 30, 1999, both of Duluth, Minnesota; to join the Gesell Family Shareholder Group, a group acting in PO 00000 Frm 00015 Fmt 4703 Sfmt 4703 concert, to acquire additional voting shares of Cherokee Bancshares, Inc., and thereby indirectly acquire voting shares of BankCherokee. 2. DDS Trust, Preston B. Steele as trustee, both of Huron, South Dakota; to acquire voting shares of Leackco Bank Holding Company, Inc., Huron, South Dakota, and thereby indirectly acquire voting shares of American Bank & Trust, Wessington Springs, South Dakota B. Federal Reserve Bank of Atlanta (Kathryn Haney, Assistant Vice President) 1000 Peachtree Street NE, Atlanta, Georgia 30309. Comments can also be sent electronically to Applications.Comments@atl.frb.org: 1. Dennis Randall Aucoin, Slaughter, Louisiana; to retain voting shares of Clinton Bancshares, Inc., and thereby indirectly retain voting shares of Landmark Bank, both of Clinton, Louisiana. 2. Lynette Elaine Ligon, Robert David Ligon, both of Clinton, Louisiana; and Alison Leslie Ligon, Ethel, Louisiana; to join the Ligon Family Control Group, a group acting in concert, to retain voting control of Clinton Bancshares, Inc., and thereby indirectly retain voting shares of Landmark Bank, both of Clinton, Louisiana. Board of Governors of the Federal Reserve System, March 30, 2021. Michele Taylor Fennell, Deputy Associate Secretary of the Board. [FR Doc. 2021–06888 Filed 4–2–21; 8:45 am] BILLING CODE P DEPARTMENT OF HEALTH AND HUMAN SERVICES Agency for Toxic Substances and Disease Registry [60Day–21–21EB; Docket No. ATSDR–2021– 0004] Proposed Data Collection Submitted for Public Comment and Recommendations Agency for Toxic Substances and Disease Registry (ATSDR), Department of Health and Human Services (HHS). ACTION: Notice with comment period. AGENCY: The Agency for Toxic Substances and Disease Registry (ATSDR), as part of its continuing effort to reduce public burden and maximize the utility of government information, invites the general public and other Federal agencies the opportunity to comment on a proposed and/or continuing information collection, as required by the Paperwork Reduction SUMMARY: E:\FR\FM\05APN1.SGM 05APN1 jbell on DSKJLSW7X2PROD with NOTICES Federal Register / Vol. 86, No. 63 / Monday, April 5, 2021 / Notices Act of 1995. This notice invites comment on a proposed information collection project titled ‘‘Evaluating the Association between Serum Concentrations of Per- and Polyfluoroalkyl Substances (PFAS) and Symptoms and Diagnoses of Selected Acute Viral Illnesses.’’ The proposed study will examine the relationship between PFAS serum levels and susceptibility to certain acute viral illnesses, including but not limited to COVID–19. DATES: ATSDR must receive written comments on or before June 4, 2021. ADDRESSES: You may submit comments, identified by Docket No. ATSDR–2021– 0004 by any of the following methods: • Federal eRulemaking Portal: Regulations.gov. Follow the instructions for submitting comments. • Mail: Jeffrey M. Zirger, Information Collection Review Office, Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS–D74, Atlanta, Georgia 30329. Instructions: All submissions received must include the agency name and Docket Number. ATSDR will post, without change, all relevant comments to Regulations.gov. Please note: Submit all comments through the Federal eRulemaking portal (regulations.gov) or by U.S. mail to the address listed above. FOR FURTHER INFORMATION CONTACT: To request more information on the proposed project or to obtain a copy of the information collection plan and instruments, contact Jeffrey M. Zirger, Information Collection Review Office, Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS– D74, Atlanta, Georgia 30329; phone: 404–639–7118; Email: omb@cdc.gov. SUPPLEMENTARY INFORMATION: Under the Paperwork Reduction Act of 1995 (PRA) (44 U.S.C. 3501–3520), Federal agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. In addition, the PRA also requires Federal agencies to provide a 60-day notice in the Federal Register concerning each proposed collection of information, including each new proposed collection, each proposed extension of existing collection of information, and each reinstatement of previously approved information collection before submitting the collection to the OMB for approval. To comply with this requirement, we are publishing this notice of a proposed data collection as described below. The OMB is particularly interested in comments that will help: VerDate Sep<11>2014 17:23 Apr 02, 2021 Jkt 253001 1. Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility; 2. Evaluate the accuracy of the agency’s estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; 3. Enhance the quality, utility, and clarity of the information to be collected; 4. Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submissions of responses; and 5. Assess information collection costs. Proposed Project Evaluating the Impact of Per- and Polyfluoroalkyl Substances (PFAS) Exposure on Susceptibility to Viral Infection—New—Agency for Toxic Substances and Disease Registry (ATSDR). Background and Brief Description Per- and poly-fluoroalkyl substances (PFAS) are a large, diverse group of thousands of chemicals. They have been used extensively in a wide range of industrial and consumer applications. Epidemiological studies have evaluated the associations between PFAS exposure and health effects in humans. Evidence from studies in occupationally exposed populations, residential populations exposed to higher levels of PFAS in drinking water, and studies in the general population suggest associations between PFAS and several health outcomes. Exposure to PFAS is nearly ubiquitous in the United States. Epidemiological studies suggest that PFAS exposure may impact the immune system and susceptibility to viral infections; however, there is little consistency in the results of studies on PFAS exposure and infectious disease. The coronavirus disease 2019 (COVID– 19) pandemic presents a unique concern and opportunity to explore this association. If PFAS affect the immune system, it is possible that they could affect susceptibility to infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV–2), the virus that causes COVID–19, or could affect severity of COVID–19. In 2019 and 2020, the Agency for Toxic Substances and Disease Registry (ATSDR) conducted statistically based PO 00000 Frm 00016 Fmt 4703 Sfmt 4703 17601 biomonitoring PFAS exposure assessments (EAs) in eight communities that had documented exposures to PFAS in drinking water. ATSDR also supported two EAs that were designed to test the PFAS Exposure Assessment Technical Tools (PEATT). PFAS concentrations were measured in serum collected from EA and PEATT assessment participants, and a questionnaire was administered to gather information to characterize each individual’s exposure. These communities were investigated under ‘‘Per- or Polyfluoroalkyl Substances Exposure Assessments [PFAS EAs]’’ (OMB Control No. 0923–0059, expiration date 06/30/2022). During the same period, ATSDR initiated a health study at the Pease International Tradeport that included measurement of PFAS serum levels and collection of information about individual exposures in participants under ‘‘Human Health Effects of Drinking Water Exposures to Per- and Polyfluoroalkyl Substances (PFAS) at Pease International Tradeport, Portsmouth, NH (The Pease Study)’’ (OMB Control No. 0923–0061, expiration date 08/31/2022). This a new two-year ATSDR information collection request (ICR) for a collaborative study between the National Center for Environmental Health (NCEH) and ATSDR. This follow-up study will recruit participants who were participated in a previous ATSDR-funded study, who have existing PFAS serum measurements, and who have given prior consent for additional contact from NCEH/ATSDR. We anticipate that the total number of participants enrolled in the NCEH/ ATSDR cohorts will be around 4,075 individuals (3,300 adults and 775 children). This study will attempt to enroll the entire universe of eligible participants; therefore, our target sample size is 4,075. The cohorts have a substantial number of participants with high PFAS exposure, as well as a sufficient range of serum PFAS concentrations to allow examination of associations between the outcomes and across a wide range of PFAS exposures. The objectives are the following: (1) To examine the association between PFAS concentrations in serum collected from existing ATSDR cohorts and the frequency of occurrence of selected syndromes (combinations of selfreported symptoms), which will be used as a proxy for viral infections; and, (2) to examine the association between PFAS concentrations in serum collected from existing ATSDR cohorts and selfreported positive test results indicating specific viral infections. E:\FR\FM\05APN1.SGM 05APN1 17602 Federal Register / Vol. 86, No. 63 / Monday, April 5, 2021 / Notices During the first three months of the two-year study period, NCEH/ATSDR will invite and consent approximately 4,075 participants (3,300 adults and 775 children) to complete a new series of questionnaires to determine whether PFAS exposure increases susceptibility to viral infections, including, but not limited to, COVID–19. Data will be collected from those who enroll in the study through an initial paper-based questionnaire and a series of four additional questionnaires over a 12- to 14-month period. Follow-up questionnaires will be offered in two modes: Web-based and paper-based. It is estimated that 75 percent of the participants will choose the web-based mode. Participants will also be given symptom diaries to improve recall after the initial and between each of the follow-up questionnaires. The total time burden requested is 12,724 hours annually. There are no costs to the respondents other than their time. ESTIMATED ANNUALIZED BURDEN HOURS Average burden per response (in hr) Total annual burden (in hr) Form name Adults .................................... Initial Questionnaire—Adult (paper) ............. Follow up Questionnaire—Adult (paper) ...... Follow up Questionnaire—Adult (REDCap) Symptom Diary ............................................. Initial Questionnaire—Child (paper) ............. Follow up Questionnaire—Child (paper) ...... Follow up Questionnaire—Child (REDCap) Symptom Diary ............................................. Initial Questionnaire—Child (paper) ............. 1,650 412 1,238 1,650 290 72 218 290 75 1 4 4 1 1 4 4 1 1 30/60 30/60 25/60 4 30/60 30/60 25/60 4 30/60 825 825 2,063 6,600 145 145 363 1,160 38 Follow up Questionnaire—Child (paper) ...... Follow up Questionnaire—Child (REDCap) Symptom Diary ............................................. 24 74 98 4 4 1 30/60 25/60 4 49 123 390 ....................................................................... ........................ ........................ ........................ 12,724 Children (7–17 years) ........... Parents of Children (3–6 years). Total ............................... Jeffrey M. Zirger, Lead, Information Collection Review Office, Office of Scientific Integrity, Office of Science, Centers for Disease Control and Prevention. [FR Doc. 2021–06882 Filed 4–2–21; 8:45 am] BILLING CODE 4163–70–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Board of Scientific Counselors, National Center for Health Statistics (BSC, NCHS) Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS). AGENCY: ACTION: Notice of meeting. In accordance with the Federal Advisory Committee Act, the CDC announces the following meeting for the Board of Scientific Counselors, National Center for Health Statistics (BSC, NCHS). This meeting is open to the public limited only by the audio (via teleconference) lines available. The public is welcome to listen to the meeting, please use the following URL https://www.cdc.gov/nchs/about/bsc/ bsc_meetings.htm that points to the BSC homepage. Further information and meeting agenda will be available on the SUMMARY: jbell on DSKJLSW7X2PROD with NOTICES Number of responses per respondent Number of respondents Type of respondent VerDate Sep<11>2014 17:23 Apr 02, 2021 Jkt 253001 BSC website including instructions for accessing the live meeting broadcast. DATES: The meeting will be held on May 19, 2021, from 11:00 a.m. to 5:30 p.m., EDT. ADDRESSES: The teleconference access is https://www.cdc.gov/nchs/about/bsc/ bsc_meetings.htm. FOR FURTHER INFORMATION CONTACT: Sayeedha Uddin, M.D., M.P.H., Executive Secretary, NCHS/CDC, Board of Scientific Counselors, 3311 Toledo Road, Room 2627, Hyattsville, Maryland 20782, Telephone (301) 458–4303; Email SUddin@cdc.gov. SUPPLEMENTARY INFORMATION: Purpose: The Board is charged with providing advice and making recommendations to the Secretary, Department of Health and Human Services; the Director, CDC; and the Director, NCHS, regarding the scientific and technical program goals and objectives, strategies, and priorities of NCHS. Matters To Be Considered: The meeting agenda includes welcome remarks and a Center update by NCHS Director; presentation on National Center for Health Statistics Strategic Planning; presentation on Synthetic Data; presentation on Changes in National Health Interview Survey Data Collection During the COVID–19 pandemic; presentation on Innovation in Vital Statistics: Nowcasting PO 00000 Frm 00017 Fmt 4703 Sfmt 9990 Techniques; and presentation on Division of Health Care Statistics Cloud Migration. Agenda items are subject to change as priorities dictate. The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry. Kalwant Smagh, Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention. [FR Doc. 2021–06905 Filed 4–2–21; 8:45 am] BILLING CODE 4163–18–P E:\FR\FM\05APN1.SGM 05APN1

Agencies

[Federal Register Volume 86, Number 63 (Monday, April 5, 2021)]
[Notices]
[Pages 17600-17602]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-06882]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Agency for Toxic Substances and Disease Registry

[60Day-21-21EB; Docket No. ATSDR-2021-0004]


Proposed Data Collection Submitted for Public Comment and 
Recommendations

AGENCY: Agency for Toxic Substances and Disease Registry (ATSDR), 
Department of Health and Human Services (HHS).

ACTION: Notice with comment period.

-----------------------------------------------------------------------

SUMMARY: The Agency for Toxic Substances and Disease Registry (ATSDR), 
as part of its continuing effort to reduce public burden and maximize 
the utility of government information, invites the general public and 
other Federal agencies the opportunity to comment on a proposed and/or 
continuing information collection, as required by the Paperwork 
Reduction

[[Page 17601]]

Act of 1995. This notice invites comment on a proposed information 
collection project titled ``Evaluating the Association between Serum 
Concentrations of Per- and Polyfluoroalkyl Substances (PFAS) and 
Symptoms and Diagnoses of Selected Acute Viral Illnesses.'' The 
proposed study will examine the relationship between PFAS serum levels 
and susceptibility to certain acute viral illnesses, including but not 
limited to COVID-19.

DATES: ATSDR must receive written comments on or before June 4, 2021.

ADDRESSES: You may submit comments, identified by Docket No. ATSDR-
2021-0004 by any of the following methods:
     Federal eRulemaking Portal: Regulations.gov. Follow the 
instructions for submitting comments.
     Mail: Jeffrey M. Zirger, Information Collection Review 
Office, Centers for Disease Control and Prevention, 1600 Clifton Road 
NE, MS-D74, Atlanta, Georgia 30329.
    Instructions: All submissions received must include the agency name 
and Docket Number. ATSDR will post, without change, all relevant 
comments to Regulations.gov.
    Please note: Submit all comments through the Federal eRulemaking 
portal (regulations.gov) or by U.S. mail to the address listed above.

FOR FURTHER INFORMATION CONTACT: To request more information on the 
proposed project or to obtain a copy of the information collection plan 
and instruments, contact Jeffrey M. Zirger, Information Collection 
Review Office, Centers for Disease Control and Prevention, 1600 Clifton 
Road NE, MS-D74, Atlanta, Georgia 30329; phone: 404-639-7118; Email: 
[email protected].

SUPPLEMENTARY INFORMATION: Under the Paperwork Reduction Act of 1995 
(PRA) (44 U.S.C. 3501-3520), Federal agencies must obtain approval from 
the Office of Management and Budget (OMB) for each collection of 
information they conduct or sponsor. In addition, the PRA also requires 
Federal agencies to provide a 60-day notice in the Federal Register 
concerning each proposed collection of information, including each new 
proposed collection, each proposed extension of existing collection of 
information, and each reinstatement of previously approved information 
collection before submitting the collection to the OMB for approval. To 
comply with this requirement, we are publishing this notice of a 
proposed data collection as described below.
    The OMB is particularly interested in comments that will help:
    1. Evaluate whether the proposed collection of information is 
necessary for the proper performance of the functions of the agency, 
including whether the information will have practical utility;
    2. Evaluate the accuracy of the agency's estimate of the burden of 
the proposed collection of information, including the validity of the 
methodology and assumptions used;
    3. Enhance the quality, utility, and clarity of the information to 
be collected;
    4. Minimize the burden of the collection of information on those 
who are to respond, including through the use of appropriate automated, 
electronic, mechanical, or other technological collection techniques or 
other forms of information technology, e.g., permitting electronic 
submissions of responses; and
    5. Assess information collection costs.

Proposed Project

    Evaluating the Impact of Per- and Polyfluoroalkyl Substances (PFAS) 
Exposure on Susceptibility to Viral Infection--New--Agency for Toxic 
Substances and Disease Registry (ATSDR).

Background and Brief Description

    Per- and poly-fluoroalkyl substances (PFAS) are a large, diverse 
group of thousands of chemicals. They have been used extensively in a 
wide range of industrial and consumer applications. Epidemiological 
studies have evaluated the associations between PFAS exposure and 
health effects in humans. Evidence from studies in occupationally 
exposed populations, residential populations exposed to higher levels 
of PFAS in drinking water, and studies in the general population 
suggest associations between PFAS and several health outcomes. Exposure 
to PFAS is nearly ubiquitous in the United States.
    Epidemiological studies suggest that PFAS exposure may impact the 
immune system and susceptibility to viral infections; however, there is 
little consistency in the results of studies on PFAS exposure and 
infectious disease. The coronavirus disease 2019 (COVID-19) pandemic 
presents a unique concern and opportunity to explore this association. 
If PFAS affect the immune system, it is possible that they could affect 
susceptibility to infection with severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, or could 
affect severity of COVID-19.
    In 2019 and 2020, the Agency for Toxic Substances and Disease 
Registry (ATSDR) conducted statistically based biomonitoring PFAS 
exposure assessments (EAs) in eight communities that had documented 
exposures to PFAS in drinking water. ATSDR also supported two EAs that 
were designed to test the PFAS Exposure Assessment Technical Tools 
(PEATT). PFAS concentrations were measured in serum collected from EA 
and PEATT assessment participants, and a questionnaire was administered 
to gather information to characterize each individual's exposure. These 
communities were investigated under ``Per- or Polyfluoroalkyl 
Substances Exposure Assessments [PFAS EAs]'' (OMB Control No. 0923-
0059, expiration date 06/30/2022).
    During the same period, ATSDR initiated a health study at the Pease 
International Tradeport that included measurement of PFAS serum levels 
and collection of information about individual exposures in 
participants under ``Human Health Effects of Drinking Water Exposures 
to Per- and Polyfluoroalkyl Substances (PFAS) at Pease International 
Tradeport, Portsmouth, NH (The Pease Study)'' (OMB Control No. 0923-
0061, expiration date 08/31/2022).
    This a new two-year ATSDR information collection request (ICR) for 
a collaborative study between the National Center for Environmental 
Health (NCEH) and ATSDR. This follow-up study will recruit participants 
who were participated in a previous ATSDR-funded study, who have 
existing PFAS serum measurements, and who have given prior consent for 
additional contact from NCEH/ATSDR. We anticipate that the total number 
of participants enrolled in the NCEH/ATSDR cohorts will be around 4,075 
individuals (3,300 adults and 775 children). This study will attempt to 
enroll the entire universe of eligible participants; therefore, our 
target sample size is 4,075. The cohorts have a substantial number of 
participants with high PFAS exposure, as well as a sufficient range of 
serum PFAS concentrations to allow examination of associations between 
the outcomes and across a wide range of PFAS exposures.
    The objectives are the following: (1) To examine the association 
between PFAS concentrations in serum collected from existing ATSDR 
cohorts and the frequency of occurrence of selected syndromes 
(combinations of self-reported symptoms), which will be used as a proxy 
for viral infections; and, (2) to examine the association between PFAS 
concentrations in serum collected from existing ATSDR cohorts and self-
reported positive test results indicating specific viral infections.

[[Page 17602]]

    During the first three months of the two-year study period, NCEH/
ATSDR will invite and consent approximately 4,075 participants (3,300 
adults and 775 children) to complete a new series of questionnaires to 
determine whether PFAS exposure increases susceptibility to viral 
infections, including, but not limited to, COVID-19. Data will be 
collected from those who enroll in the study through an initial paper-
based questionnaire and a series of four additional questionnaires over 
a 12- to 14-month period. Follow-up questionnaires will be offered in 
two modes: Web-based and paper-based. It is estimated that 75 percent 
of the participants will choose the web-based mode. Participants will 
also be given symptom diaries to improve recall after the initial and 
between each of the follow-up questionnaires.
    The total time burden requested is 12,724 hours annually. There are 
no costs to the respondents other than their time.

                                        Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
                                                                                      Average
                                                     Number of       Number of      burden per     Total annual
      Type of respondent            Form name       respondents    responses per   response  (in    burden  (in
                                                                    respondent          hr)             hr)
----------------------------------------------------------------------------------------------------------------
Adults........................  Initial                    1,650               1           30/60             825
                                 Questionnaire--
                                 Adult (paper).
                                Follow up                    412               4           30/60             825
                                 Questionnaire--
                                 Adult (paper).
                                Follow up                  1,238               4           25/60           2,063
                                 Questionnaire--
                                 Adult (REDCap).
                                Symptom Diary...           1,650               1               4           6,600
Children (7-17 years).........  Initial                      290               1           30/60             145
                                 Questionnaire--
                                 Child (paper).
                                Follow up                     72               4           30/60             145
                                 Questionnaire--
                                 Child (paper).
                                Follow up                    218               4           25/60             363
                                 Questionnaire--
                                 Child (REDCap).
                                Symptom Diary...             290               1               4           1,160
Parents of Children (3-6        Initial                       75               1           30/60              38
 years).                         Questionnaire--
                                 Child (paper).
                                Follow up                     24               4           30/60              49
                                 Questionnaire--
                                 Child (paper).
                                Follow up                     74               4           25/60             123
                                 Questionnaire--
                                 Child (REDCap).
                                Symptom Diary...              98               1               4             390
                                                 ---------------------------------------------------------------
    Total.....................  ................  ..............  ..............  ..............          12,724
----------------------------------------------------------------------------------------------------------------


Jeffrey M. Zirger,
Lead, Information Collection Review Office, Office of Scientific 
Integrity, Office of Science, Centers for Disease Control and 
Prevention.
[FR Doc. 2021-06882 Filed 4-2-21; 8:45 am]
BILLING CODE 4163-70-P